Jul. 5 at 12:17 AM
This is an update to our 6/19/26 post reflecting multiples of a pool of pre-commercial stage bios with active PDUFA dates. The XBI is up 14% since. Most of the bios in this peer group are up consistently except for
$CAPR which is down ~25% since the FDA set up an AdCom meeting to review their Deramiocel submission.
$SRRK continues to trade at meaningfully higher multiples than these peers. Of the 16 analysts that cover SRRK, 7 provide 9-year estimates. All 7 peg FY35 (aka peak) sales at
$1.7 to
$2.2B. This is not investment advice. There could be very good reason why SRRK trades at such a high multiple. Like last time, we'd genuinely appreciate your perspective on SRRK's multiples
$VRDN 's Lumvoa for TED was approved on 6/26/26. We're leaving VRDN just because. VRDN trades at the lowest multiple in this peer group. We've read interesting pros & cons
We sold
$VERA at
$37 which shows how good we are.
We source our share price & market cap data via automated Excel tools. Note
$SVRA comments
